Latest Kaiser Health News Stories
More than 70 drugs approved from 2001 through 2010 ran into safety concerns later that resulted in withdrawals from the market, “black box” warnings or other actions.
You might save money on premiums with a high-deductible health plan only to find you’re spending more on the back end. These tips will help you minimize your expenses for medical treatment and prescriptions.
A California lawmaker wants to strengthen collaboration among public agencies to bring down costs to taxpayers.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Such efforts have previously failed in the face of opposition from the drug industry, which questions their effectiveness and contends prices reflect research and development costs.
The opioid addiction crisis has led to a crackdown on prescriptions for chronic pain patients, who are increasingly given less addictive painkillers along with referrals for acupuncture, physical therapy, massage and even yoga.
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
Blue Shield of California is hoping to steer consumers to “preferred” pharmacies where drugs are cheaper and copays lower.
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Hundreds of drug brands are being made in giant contract facilities. When a plant shuts down, a widespread drain on supply can result.
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.